Skip to main content
CDK4/6 inhibitors: Should they be stopped in the face of COVID-19?
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
CDK4/6 inhibitors: Should they be stopped in the face of COVID-19?
User login
Username
Password
Reset your password
Concept
Lead
score
COVID-19
1
1
Breast Cancer
0
0.85
Liver Metastases
0
0.69
Cancer
0
0.64
Metastasis
0
0.64
Hepatocellular Carcinoma
0
0.6
Targeted Cancer Therapy
0
0.55
Advanced and Metastatic Breast Cancer
0
0.49
Biologic Therapy
0
0.47
Breast
0
0.37
Toxicology
0
0.36
Face
0
0.28
Pandemic
0
0.28
Chemotherapy
0
0.18
Endocrine Therapy
0
0.18
Europe
0
0.18
Liver
0
0.18
Adverse Effects
0
0.09
Analgesia
0
0.09
Aromatase Inhibitors
0
0.09
Clinical Research
0
0.09
Dorsum
0
0.09
Immunocompromise
0
0.09
Medical Oncology
0
0.09
Myelosuppression
0
0.09
Quality of Life
0
0.09
Radiation Therapy
0
0.09
Receptors
0
0.09
Surgery
0
0.09
Neutropenia
0
0.07
Pain Management
0
0.07
Patient Safety
0
0.07
Specialty
Lead
score
Hematology-Oncology
1
1
Internal Medicine
0
0.9